| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2023-03-14 | Ascelia Pharma | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Market – Next Steps Towards Launch | Pressreleaser | Ladda ner | Visa Stäng |
|
Pressreleaser |
Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Market – Next Steps Towards LaunchAscelia Pharma AB (publ) (ticker: ACE), today presented updates on expected mid-2023 SPARKLE Phase 3 readout, as well as the launch strategy to address the 800 million USD global market opportunity with 100,000 procedures in the target patient population in the US alone. Investors, analysts, and media are invited to join today’s Investor Update with a live Q&A webcast at 14:00 CET. The event consists of recorded presentations from Ascelia Pharma executives and a live Q&A webcast. The livestreamed Q&A webcast will take place today, Tuesday, March 14 from 14:00 CET. The presentations are now available on Ascelia Pharma’s website www.ascelia.com . “We have three key objectives for Ascelia Pharma in 2023. We met the first one by completing patient enrollment in SPARKLE in February. Headline result with the primary endpoint will be available in the middle of this year and together with our launch preparations those are our key activities to successfully pursue our mission to improve the life of people living with cancer by offering better treatment options.” said Magnus Corfitzen, CEO of Ascelia Pharma. “The addressable market for Orviglance has a global value of 800 million dollars annually. This includes our previous estimate for the US, Europe, and Japan, as well as other relevant markets. Our update today also provides further details on pricing benchmarks and volume estimates; with 100,000 abdominal imaging procedures annually in our target patient population in the US alone”, says Julie Waras Brogren, Deputy CEO and CCO of Ascelia Pharma. The Investor Update presentations include:
The presentations are now available on Ascelia Pharma’s website www.ascelia.com A recording of the Q&A webcast will be published on Ascelia Pharma’s website after the event. All presentations will be held in English. |
||||
| 2023-03-14 | Ascelia Pharma | Välkommen till Ascelia Pharma Investor Update: Att ta Orviglance till marknaden – nästa steg mot lansering | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-13 | Ascelia Pharma | Ascelia Pharma sörjer styrelseledamot René Spogárds bortgång | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-13 | Ascelia Pharma | Ascelia Pharma Mourns the Passing of Board Member René Spogárd | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-13 | Ascelia Pharma | Ett tredje amerikanskt patentet stärker patentskyddet för Ascelia Pharmas Oncoral (Daglig tablett irinotekan) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-13 | Ascelia Pharma | Third US patent strengthens patent protection for Ascelia Pharma's Oncoral (daily tablet irinotecan) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-06 | Ascelia Pharma | INBJUDAN TILL ASCELIA PHARMAS INVESTERARUPPDATERING: ATT TA ORVIGLANCE TILL MARKNADEN – NÄSTA STEG MOT LANSERING | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-06 | Ascelia Pharma | INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-03 | Ascelia Pharma | Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-03-03 | Ascelia Pharma | Ascelia Pharma rapporterar att den sista patientens sista besök (LPLV) har genomförts i fas 3-studien SPARKLE med Orviglance vilken nu inkluderar 85 patienter som slutfört studien. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-28 | Ascelia Pharma | Change in number of shares and votes in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-28 | Ascelia Pharma | Ändring av antalet aktier och röster i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-24 | Ascelia Pharma | Ascelia Pharma når viktig milstolpe - slutför patientrekryteringen till Orviglance fas 3-studie, SPARKLE | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-24 | Ascelia Pharma | Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-21 | Ascelia Pharma | Ascelia Pharma beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitamentsprogram | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-21 | Ascelia Pharma | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-13 | Penser Access | Penser Access: Q4 – fullt fokus på patientrekrytering - Ascelia Pharma | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-02-10 | Ascelia Pharma | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-02-10 | Ascelia Pharma | KVARTALSRAPPORT Q4 2022: Fas 3 studien för Orviglance, SPARKLE, förväntas avslutas i första kvartalet 2023. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-01-27 | Ascelia Pharma | 71 patienter har slutfört SPARKLE-studien | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-01-27 | Ascelia Pharma | 71 patients have completed the SPARKLE study | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-29 | Ascelia Pharma | 65 patienter har slutfört SPARKLE-studien | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-29 | Ascelia Pharma | 65 patients have completed the SPARKLE study | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-12 | Finansinspektionen | Finansinspektionen: Flaggningsmeddelande i Ascelia Pharma AB | Pressreleaser | Visa Stäng |
|
|
||||
| 2022-12-12 | Penser Access | Penser Access: Nytt rekryteringsmål - Ascelia Pharma | Analyser | Visa Stäng |
|
|
||||
| 2022-12-08 | Analysguiden | Analysguiden: ANALYS Ascelia Pharma: Trög rekrytering i fas 3 | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-07 | Finansinspektionen | Finansinspektionen: Flaggningsmeddelande i Ascelia Pharma AB | Pressreleaser | Visa Stäng |
|
|
||||
| 2022-12-06 | Ascelia Pharma | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-06 | Ascelia Pharma | Nya starka Orviglance-data stöder framgångsrik avslutning av SPARKLE-studien med betydligt färre patienter | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-02 | Ascelia Pharma | Valberedningen utsedd i Ascelia Pharma AB inför årsstämman 2023 | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-02 | Ascelia Pharma | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-11-30 | Ascelia Pharma | ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-11-30 | Ascelia Pharma | ASCELIA PHARMA PRESENTERAR RESULTAT FRÅN ORVIGLANCE FOOD EFFECT-STUDIE VID RSNA 2022 SOM VISAR STARK FÖRBÄTTRING AV VISUALISERING AV LEVERN BÅDE MED LÄTT MÅLTID OCH I FASTANDE TILLSTÅND | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-11-08 | Penser Access | Penser Access: Sista patienten inom räckhåll - Ascelia Pharma | Analyser | Visa Stäng |
|
|
||||
| 2022-11-04 | Ascelia Pharma | KVARTALSRAPPORT Q3 2022: Framgångsrik slutrapportering i två av tre studier inför regulatorisk ansökan | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-11-04 | Ascelia Pharma | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-10-05 | Ascelia Pharma | Ascelia Pharma expands its leadership team | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-10-05 | Ascelia Pharma | Ascelia Pharma utökar sin ledningsgrupp | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-09-28 | Ascelia Pharma | Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-09-28 | Ascelia Pharma | Ascelia Pharma meddelar framgångsrik slutrapportering av studie av Orviglance vid nedsatt leverfunktion | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-23 | Analysguiden | Analysguiden: ANALYS Ascelia Pharma: Fas 3 närmar sig slutet | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-22 | Penser Access | Penser Access: Ingen dramatik i Q2 - Ascelia Pharma | Analyser | Visa Stäng |
|
|
||||
| 2022-08-18 | Ascelia Pharma | Halvårsrapport 2022: Starka resultat från Orviglance mateffektstudie | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-18 | Ascelia Pharma | Half-year report 2022: Strong results from Orviglance Food Effect Study | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-11 | Ascelia Pharma | Ascelia Pharma presenterar Orviglance mateffektstudie vid RSNA 2022-konferensen | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-11 | Ascelia Pharma | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-20 | Ascelia Pharma | Ascelia Pharma utser Déspina Georgiadou Hedin till ny CFO | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-20 | Ascelia Pharma | Ascelia Pharma appoints Déspina Georgiadou Hedin as new CFO | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-01 | Ascelia Pharma | Resultat från Orviglance jämförelsestudie med gadolinium presenterad vid ESGAR 2022-konferensen | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-01 | Ascelia Pharma | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-31 | Ascelia Pharma | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-31 | Ascelia Pharma | Ascelia Pharmas andra amerikanska patent för Oncoral (oralt irinotekan) stärker skyddet ytterligare | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-16 | Analysguiden | Analysguiden: ANALYS Ascelia Pharma: Läkarstöd för Orviglance | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-12 | Penser Access | Penser Access: Blickar framåt - Ascelia Pharma | Analyser | Visa Stäng |
|
|
||||
| 2022-05-11 | Ascelia Pharma | Kvartalsrapport Q1 2022: Starkt stöd till Orviglance från vårdpersonal | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-11 | Ascelia Pharma | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-10 | Ascelia Pharma | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-10 | Ascelia Pharma | Ascelia Pharmas mateffektstudie visar att Orviglances bildförbättring av levern inte minskas av lätt måltid | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-05 | Ascelia Pharma | Kommuniké från årsstämma den 5 maj 2022 i Ascelia Pharma AB | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-05 | Ascelia Pharma | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-11 | Ascelia Pharma | Ascelia Pharma publicerar årsredovisning för 2021 | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-11 | Ascelia Pharma | Ascelia Pharma publishes Annual Report for 2021 | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-05 | Ascelia Pharma | KALLELSE TILL ÅRSSTÄMMA I ASCELIA PHARMA AB | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-05 | Ascelia Pharma | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-01 | Ascelia Pharma | CFO Kristian Borbos to leave Ascelia Pharma | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-01 | Ascelia Pharma | CFO Kristian Borbos lämnar Ascelia Pharma | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-03-31 | Ascelia Pharma | Number of shares and votes in Ascelia Pharma AB | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-03-31 | Ascelia Pharma | Antal aktier och röster i Ascelia Pharma AB | Analyser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-03-31 | Ascelia Pharma | Ascelia Pharma AB: HC Andersen Capital: Release of new Ascelia Pharma investment case | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
Kommande händelser
